These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings. Krishnan A, Arslanoglu A, Yildirm N, Silbergleit R, Aygun N. J Comput Assist Tomogr; 2009; 33(2):298-304. PubMed ID: 19346864 [Abstract] [Full Text] [Related]
3. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Reid IR, Bolland MJ, Grey AB. Bone; 2007 Sep; 41(3):318-20. PubMed ID: 17572168 [Abstract] [Full Text] [Related]
10. Is exposure of the jawbone mandatory for establishing the diagnosis of bisphosphonate-related osteonecrosis of the jaw? Yarom N, Fedele S, Lazarovici TS, Elad S. J Oral Maxillofac Surg; 2010 Mar; 68(3):705. PubMed ID: 20171493 [No Abstract] [Full Text] [Related]
13. American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-Related Osteonecrosis of the Jaws-2009 update: the need to refine the BRONJ definition. Colella G, Campisi G, Fusco V. J Oral Maxillofac Surg; 2009 Dec; 67(12):2698-9. PubMed ID: 19925998 [No Abstract] [Full Text] [Related]
14. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series. Landesberg R, Wilson T, Grbic JT. Dent Today; 2006 Aug; 25(8):52, 54-7. PubMed ID: 16925161 [Abstract] [Full Text] [Related]
15. Osteonecrosis of the jaw related to the use of bisphosphonates. Van den Wyngaert T, Huizing MT, Vermorken JB. Curr Opin Oncol; 2007 Jul; 19(4):315-22. PubMed ID: 17545793 [Abstract] [Full Text] [Related]
16. Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment. Wehrhan F, Hyckel P, Amann K, Ries J, Stockmann P, Schlegel K, Neukam F, Nkenke E. Oral Dis; 2011 May; 17(4):433-42. PubMed ID: 21366807 [Abstract] [Full Text] [Related]
17. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. J Clin Oncol; 2005 Dec 01; 23(34):8580-7. PubMed ID: 16314620 [Abstract] [Full Text] [Related]
18. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children? Brown JJ, Ramalingam L, Zacharin MR. Clin Endocrinol (Oxf); 2008 Jun 01; 68(6):863-7. PubMed ID: 18221397 [Abstract] [Full Text] [Related]
19. Antiresorptive drug-related osteonecrosis of the jaw. Uyanne J, Calhoun CC, Le AD. Dent Clin North Am; 2014 Apr 01; 58(2):369-84. PubMed ID: 24655528 [Abstract] [Full Text] [Related]
20. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates? Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gligorov J, Väänänen K, Pylkkänen L, Pecherstorfer M, Aapro MS. Crit Rev Oncol Hematol; 2007 Dec 01; 64(3):198-207. PubMed ID: 17855108 [Abstract] [Full Text] [Related] Page: [Next] [New Search]